Larvol Delta - Candel-Therapeutics-Reports-Extended-Clinical-Benet-Over-Multiple-Clinical-Endpoints-in-Patients-from-Phase-3-Trial-of-Aglatimagene-Besadenovec-CAN2409-in-Localized-Prostate-Cancer-Under-Prolonged-Followup-at-AUA-2026-Annual-Meeting

ProstAtak (aglatimagene besadenovec) - Candel Therap

https://www.globenewswire.com/news-release/2026/05/15/3296125/0/en/Candel-Therapeutics-Reports-Extended-Clinical-Benefit-Over-Multiple-Clinical-Endpoints-in-Patients-from-Phase-3-Trial-of-Aglatimagene-Besadenovec-CAN-2409-in-Localized-Prostate-Can.html

May 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next